# US 2024/0123089 A1 · Compositions and methods for the targeting of pcsk9

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0123089 A1
- Document ID: US20240123089A1
- Status: Published application
- Kind: A1
- Application number: 18/516,840
- Filed: 2023-11-21
- Published: 2024-04-18
- Earliest claimed: 2022-06-07
- Assignees: Scribe Therapeutics Inc.
- Applicants: Scribe Therapeutics Inc.
- Inventors: Jason FERNANDES; Sean HIGGINS; Sarah DENNY; Ross WHITE; Emeric Jean Marius CHARLES; Addison WRIGHT; Benjamin DEMAREE; Manuel MOHR; Wenyuan ZHOU; Benjamin OAKES
- Web page: https://patentgrep.com/patent/US20240123089A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C07K 14/4703: {Inhibitors; Suppressors}
- C12N 9/1007: {Methyltransferases (general) (2.1.1.)}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- C12N 15/907: {in mammalian cells}
- C12Y 201/01037: DNA (cytosine-5-)-methyltransferase (2.1.1.37)
- C12Y 201/01072: Site-specific DNA-methyltransferase (adenine-specific) (2.1.1.72)
- C12Y 201/01113: Site-specific DNA-methyltransferase (cytosine-N4-specific) (2.1.1.113)
- C07K 2319/09: containing a nuclear localisation signal
- C07K 2319/80: containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K 2319/81: containing a Zn-finger domain for DNA binding
- C07K 2319/85: containing an RNA binding domain
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2310/531: Stem-loop; Hairpin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

Provided herein are gene repressor systems comprising fusion proteins, such as fusion proteins comprising a DNA binding domain such as a TALE, zinc finger or catalytically-dead CRISPR protein and guide nucleic acid (gRNA), which are useful in the repression of a proprotein convertase subtilisin kexin Type 9 (PCSK9) gene. Also provided are methods of using such systems to repress transcription of PCSK9.

## Claims

### Claim 1

A system comprising a repressor fusion protein and a guide ribonucleic acid (gRNA), wherein the repressor fusion protein comprises:
(a) a catalytically-dead CRISPR protein;
(b) a repressor domain (RD1);
(c) a DNMT3A catalytic domain (DNMT3A); and
(d) a DNMT3L domain (DNMT3L),
wherein the gRNA comprises a targeting sequence complementary to a proprotein convertase subtilisin/kexin Type 9 (PCSK9) gene target nucleic acid sequence, and wherein the repressor fusion protein is capable of forming a ribonucleoprotein (RNP) with the gRNA.

### Claim 2 (depends on 1)

The system of claim 1, wherein the RNP is capable of repressing transcription of the PCSK9 gene upon binding to the PCSK9 gene target nucleic acid sequence.

### Claim 3 (depends on 1)

The system of claim 1, wherein the repressor fusion protein comprises, from N- to C-terminus:
(a) the DNMT3A;
(b) the DNMT3L;
(c) the catalytically-dead CRISPR protein; and
(d) the RD1; or
wherein the repressor fusion protein comprises, from N- to C-terminus:
(a) the DNMT3A;
(b) the DNMT3L;
(c) the RD1; and
(d) the catalytically-dead CRISPR protein.

### Claim 4 (depends on 1)

The system of claim 1, wherein the catalytically-dead CRISPR protein is a catalytically-dead Class 2 Type II protein, a catalytically-dead Class 2 Type V protein, or a catalytically-dead Class 2 Type VI protein.

### Claim 5 (depends on 4)

The system of claim 4, wherein the catalytically-dead Type II protein is a catalytically-dead Cas9 protein, or wherein the catalytically-dead Type V protein is a catalytically-dead CasX (dCasX).

### Claim 6 (depends on 5)

The system of claim 5, wherein the dCasX comprises a sequence selected from the group consisting of SEQ ID NOS: 4-29, or a sequence having at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity thereto.

### Claim 7 (depends on 1)

The system of claim 1, wherein the RD1 comprises an amino acid sequence motif selected from the group consisting of:
(a) PX1X2X3X4X5X6EX7, wherein
i) X1 is A, D, E, or N,
ii) X2 is L or V,
iii) X3 is I or V,
iv) X4 is S, T, or F,
v) X5 is H, K, L, Q, R or W,
vi) X6 is L or M, and
vii) X7 is G, K, Q, or R;
(b) X1X2X3X4GX5X6X7X8X9, wherein
i) X1 is L or V,
ii) X2 is A, G, L, T or V,
iii) X3 is A, F, or S,
iv) X4 is L or V,
v) X5 is C, F, H, I, L or Y,
vi) X6 is A, C, P, Q, or S,
vii) X7 is A, F, G, I, S, or V,
viii) X8 is A, P, S, or T, and
ix) X9 is K or R;
(c) QX1X2LYRX3VMX4 (SEQ ID NO: 1727), wherein
i) X1 is K or R,
ii) X2 is A, D, E, G, N, S, or T,
iii) X3 is D, E, or S, and
iv) X4 is L or R;
(d) X1X2X3FX4DVX5X6X7FX8X9X10X11 (SEQ ID NO: 1728), wherein
i) X1 is A, L, P, or S,
ii) X2 is L or V,
iii) X3 is S or T,
iv) X4 is A, E, G, K, or R,
v) X5 is A or T,
vi) X6 is I or V,
vii) X7 is D, E, N, or Y,
viii) X8 is S or T,
ix) X9 is E, P, Q, R, or W,
x) X10 is E or N, and
xi) X11 is E or Q;
(e) X1X2X3PX4X5X6X7X8X9X10, wherein
i) X1 is E, G, or R,
ii) X2 is E or K,
iii) X3 is A, D, or E,
iv) X4 is C or W,
v) X5 is I, K, L, M, T, or V,
vi) X6 is I, L, P, or V,
vii) X7 is D, E, K, or V,
viii) Xs is E, G, K, P, or R,
ix) X9 is A, D, R, G, K, Q, or V, and
x) X10 is D, E, G, I, L, R, S, or V;
(f) LYX1X2VMX3EX4X5X6X7X8X9X10 (SEQ ID NO: 1729), wherein
i) X1 is K or R,
ii) X2 is D or E,
iii) X3 is L, Q, or R,
iv) X4 is N or T,
v) X5 is F or Y,
vi) X6 is A, E, G, Q, R, or S,
vii) X7 is H, L, or N,
viii) X8 is L or V,
ix) X9 is A, G, I, L, T, or V, and
x) X10 is A, F, or S,
(g) FX1DVX2X3X4FX5X6X7EWX8(SEQ ID NO: 1730), wherein
i) X1 is A, E, G, K, or R,
ii) X2 is A, S, or T,
iii) X3 is I or V,
iv) X4 is D, E, N, or Y,
v) X5 is S or T,
vi) X6 is E, L, P, Q, R, or W,
vii) X7 is D or E, and
viii) X8 is A, E, G, Q, or R;
(h) X1PX2X3X4X5X6LEX7X8X9X10X11X12, wherein
i) X1 is K or R,
ii) X2 is A, D, E, or N,
iii) X3 is I, L, M, or V,
iv) X4 is I or V,
v) X5 is F, S, or T,
vi) X6 is H, K, L, Q, R, or W,
vii) X7 is K, Q, or R,
viii) X8 is E, G, or R,
ix) X9 is D, E, or K,
x) X10 is A, D, or E,
xi) X11 is L or P, and
xii) X12 is C or W; and
(i) X1LX2X3X4QX5X6, wherein
i) X1 is C, H, L, Q, or W,
ii) X2 is D, G, N, R, or S,
iii) X3 is L, P, S, or T,
iv) X4 is A, S, or T,
v) X5 is K or R, and
vi) X6 is A, D, E, K, N, S, or T.

### Claim 8 (depends on 1)

The system of claim 1, wherein the RD1 comprises an amino acid sequence motif selected from the group consisting of:
(a) DVAVYFSPEEWGCL (SEQ ID NO: 2945);
(b) X1X2X3QX4X5LY, wherein
i) X1 is A, D, G, N, R, or S,
ii) X2 is P, S, or T,
iii) X3 is A, S, or T,
iv) X4 is K or R, and
v) X5 is A, D, K, N, S, or T;
(c) X1KPX2X3X4X5X6, wherein
i) X1 is A, P, or S,
ii) X2 is A, D, or E,
iii) X3 is L, M, or V,
iv) X4 is I or V,
v) X5 is F, S, or T, and
vi) X6 is H, K, L, Q, R, or W;
(d) LEX1X2X3X4X5X6, wherein
i) X1 is E, K, Q or R,
ii) X2 is E, G, or R,
iii) X3 is A, D, E, or K,
iv) X4 is A, D, or E,
v) X5 is L or P, and
vi) X6 is C or W; and
(e) X1VMLEX2YX3X4X5X6SX7X8X9 (SEQ ID NO: 2946), wherein
i) X1 is D or E,
ii) X2 is N or T,
iii) X3 is A, E, G, Q, R, or S,
iv) X4 is H or N,
v) X5 is L, M, or V,
vi) X6 is A, L, or V,
vii) X7 is L or V,
viii) X8 is A, G, or V, and
ix) X9 is C, F, or L.

### Claim 9 (depends on 1)

The system of claim 1, wherein the RD1 comprises a sequence selected from the group consisting of SEQ ID NOS: 128-1726, or a sequence having at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity thereto.

### Claim 10 (depends on 1)

The system of claim 1, wherein the RD1 comprises a sequence of SEQ ID NO: 129, or a sequence having at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity thereto.

### Claim 11 (depends on 1)

The system of claim 1, wherein the DNMT3A comprises a sequence of SEQ ID NO: 126, or a sequence having at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity thereto.

### Claim 12 (depends on 1)

The system of claim 1, wherein the DNMT3L comprises a sequence of SEQ ID NO: 127, or a sequence having at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity thereto.

### Claim 13 (depends on 1)

The system of claim 1, wherein the repressor fusion protein comprises one or more linker peptides, and/or one or more nuclear localization signals (NLS).

### Claim 14 (depends on 13)

The system of claim 13, wherein the repressor fusion protein comprises, from N- to C-terminus:
(a) NLS-DNMT3A-DNMT3L-dCasX-RD1-NLS;
(b) NLS-dCasX-RD1-NLS-DNMT3A-DNMT3L;
(c) NLS-dCasX-DNMT3A-DNMT3L-RD1-NLS;
(d) NLS-RD1-DNMT3A-DNMT3L-dCasX-NLS; or
(e) NLS-DNMT3A-DNMT3L-RD1-dCasX-NLS.

### Claim 15 (depends on 13)

The system of claim 13, wherein the repressor fusion protein comprises a DNA methyltransferase (DNMT) 3A ATRX-DNMT3-DNMT3L domain (ADD).

### Claim 16 (depends on 15)

The system of claim 15, wherein the ADD comprises a sequence of SEQ ID NO: 125, or a sequence having at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity thereto.

### Claim 17 (depends on 15)

The system of claim 15, wherein the repressor fusion protein comprises, from N- to C-terminus:
(a) NLS-ADD-DNMT3A-DNMT3L-dCasX-RD1-NLS;
(b) NLS-dCasX-RD1-NLS-ADD-DNMT3A-DNMT3L;
(c) NLS-dCasX- ADD-DNMT3A-DNMT3L-RD1-NLS;
(d) NLS-RD1-ADD-DNMT3A-DNMT3L-dCasX-NLS; or
(e) NLS-ADD-DNMT3A-DNMT3L-RD1-dCasX-NLS.

### Claim 18 (depends on 1)

The system of claim 1, wherein the PCSK9 gene target nucleic acid sequence is:
(a) within 1 kilobase (kb) of a transcription start site (TSS) in the PCSK9 gene;
(b) within 1 kb of an enhancer of the PCSK9 gene.
(c) within the 5′ untranslated region of the PCSK9 gene;
(d) within the 3′ untranslated region of the PCSK9 gene; or
(e) within an exon of the PCSK9 gene.

### Claim 19 (depends on 18)

The system of claim 18, wherein the PCSK9 gene target nucleic acid sequence is within exon 1 of the PCSK9 gene.

### Claim 20 (depends on 1)

The system of claim 1, wherein the gRNA is a single-molecule gRNA (sgRNA) and comprises a scaffold stem loop comprising the sequence of CCAGCGACUAUGUCGUAGUGG (SEQ ID NO: 1822), or a sequence with at least 1, 2, 3, 4 or 5 mismatches thereto.

### Claim 21 (depends on 1)

The system of claim 1, wherein the gRNA comprises a scaffold comprising a sequence selected from the group consisting of SEQ ID NOS: 1744-1821, or a sequence having at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% sequence identity thereto.

### Claim 22 (depends on 1)

The system of claim 1, wherein the gRNA is chemically modified.

### Claim 23

A composition comprising a first nucleic acid and a second nucleic acid, wherein
(a) the first nucleic acid comprise a guide ribonucleic acid (gRNA) comprising a targeting sequence complementary to a proprotein convertase subtilisin kexin Type 9 (PCSK9) gene target nucleic acid sequence, wherein the gRNA is capable of forming a ribonucleoprotein (RNP) with a repressor fusion protein;
(b) the second nucleic acid encodes a repressor fusion protein comprising:
i) a catalytically-dead CRISPR protein;
ii) a repressor domain (RD1);
iii) a DNMT3A catalytic domain (DNMT3A); and
iv) a DNMT3L domain (DNMT3L); or
(c) the second nucleic acid encodes a repressor fusion protein comprising:
v) a catalytically-dead CRISPR protein;
vi) a repressor domain (RD1);
vii) a DNA methyltransferase (DNMT) 3A ATRX-DNMT3-DNMT3L domain (ADD);
viii) a DNMT3A catalytic domain (DNMT3A); and
ix) a DNMT3L domain (DNMT3L).

### Claim 24 (depends on 23)

A lipid nanoparticle (LNP) comprising the composition of claim 23.

### Claim 25 (depends on 23)

A method of repressing transcription of a PCSK9 gene in a population of cells, the method comprising introducing into the cells the composition of claim 23, wherein transcription of the PCSK9 gene is repressed by the repressor fusion protein.

### Claim 26

A method of treating a PCSK9-related disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective dose of a composition comprising a first nucleic acid and a second nucleic acid, wherein:
(a) the first nucleic acid comprises a guide ribonucleic acid (gRNA) comprising a targeting sequence complementary to a proprotein convertase subtilisin kexin Type 9 (PCSK9) gene target nucleic acid sequence, wherein the gRNA is capable of forming a ribonucleoprotein (RNP) with a repressor fusion protein;
(b) the second nucleic acid encodes a repressor fusion protein, wherein the second nucleic acid is an mRNA comprising sequences encoding:
i) a catalytically-dead CRISPR protein;
ii) a repressor domain (RD1);
iii) a DNMT3A catalytic domain (DNMT3A); and
iv) a DNMT3L domain (DNMT3L); or
(c) the second nucleic acid encodes a repressor fusion protein, wherein the second nucleic acid is an mRNA comprising sequences encoding:
i) a catalytically-dead CRISPR protein;
ii) a repressor domain (RD1);
iii) a DNMT3A catalytic domain (DNMT3A);
iv) a DNMT3L domain (DNMT3L); and
v) a DNA methyltransferase (DNMT) 3A ATRX-DNMT3-DNMT3L domain (ADD).

### Claim 27 (depends on 26)

The method of claim 26, wherein the composition is encapsulated in an LNP.

### Claim 28 (depends on 27)

The method of claim 27, wherein the LNP comprises one or more components selected from the group consisting of an ionizable lipid, a helper phospholipid, a polyethylene glycol (PEG)-modified lipid, and cholesterol or a derivative thereof.

### Claim 29 (depends on 26)

The method of claim 26, wherein the PCSK9-related disease is autosomal dominant hypercholesterolemia (ADH), hypercholesterolemia, elevated total cholesterol levels, hyperlipidemia, elevated low-density lipoprotein (LDL) levels, elevated LDL-cholesterol levels, reduced high-density lipoprotein levels, liver steatosis, coronary heart disease, ischemia, stroke, peripheral vascular disease, thrombosis, type 2 diabetes, high elevated blood pressure, atherosclerosis, obesity, aortic stenosis, elevated PCSK9 levels, or a combination thereof.
